Nomura Securities Maintains a 'Neutral' on Sprint (S); Analyst Day Handbook
Get Alerts S Hot Sheet
Price: $22.32 -0.62%
Rating Summary:
24 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 16 | New: 6
Rating Summary:
24 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 16 | New: 6
Join SI Premium – FREE
Nomura Securities maintains a 'Neutral' on Sprint (NYSE: S) price target of $4.00.
Nomura analyst, Mike McCormack, said, "Sprint will be hosting its strategy update this Friday, October 7 at 9:30am. We view the Strategy Update as a key opportunity for Sprint to provide clarity on what we believe are pivotal issues for investors. We believe investors should evaluate the proposed strategy through the lens of funding, and then appropriately evaluate risk. By our analysis, Sprint’s cash flow profile has changed considerably since the debates on future investments were introduced, with the wireless business now a net drag on 2Q11 consolidated cash flow, in our view."
For more ratings news on Sprint click here and for the rating history of Sprint click here.
Shares of Sprint closed at $2.73 yesterday.
Nomura analyst, Mike McCormack, said, "Sprint will be hosting its strategy update this Friday, October 7 at 9:30am. We view the Strategy Update as a key opportunity for Sprint to provide clarity on what we believe are pivotal issues for investors. We believe investors should evaluate the proposed strategy through the lens of funding, and then appropriately evaluate risk. By our analysis, Sprint’s cash flow profile has changed considerably since the debates on future investments were introduced, with the wireless business now a net drag on 2Q11 consolidated cash flow, in our view."
For more ratings news on Sprint click here and for the rating history of Sprint click here.
Shares of Sprint closed at $2.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SentinelOne (S) Reiterated at Market Outperform by Citizens Amid Customer Traction
- UBS Upgrades Multi Commodity Exchange of India Ltd (MCX:IN) to Buy
- BTIG Reiterates Buy Rating on Humacyte (HUMA)
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
NomuraSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share